← ORIC: big moves and long-term fundamentals中文

ORIC Pharmaceuticals: The Long View

What the filings say about its story, dilution and cash runway.

Last updated Oct 27, 2026 · Reflects: 10-K FY2025 and the 10-Q for Q2 2026

This page is information, not investment advice.

Sources used most:

1. In one paragraph

Last updated Oct 27, 2026. Reflects the 10-K FY2025 and the 10-Q for Q2 2026.

ORIC is a clinical-stage cancer drug developer. It has no products on sale, has never generated revenue and reports one operating segment; it pays for its work by selling shares (10-Q, note 1). Its two drugs are rinzimetostat, a pill in a Phase 3 trial (a large trial intended to support approval) for advanced prostate cancer, and enozertinib, a pill in Phase 1b (an early trial of safety, dose and first signs of activity) for lung cancer with mutations in EGFR, a protein involved in cell-growth signalling.

  • In 2025 it recorded $143.0M of operating expenses: research and development $109.8M (77%) and general and administrative $33.2M (23%). Outside R&D costs were $25.1M for rinzimetostat and $30.8M for enozertinib. Other income, net, of $13.5M brought the net loss to $129.5M (10-K, MD&A).
  • ORIC licensed rinzimetostat worldwide from Mirati (now part of Bristol Myers Squibb) with no milestones or royalties.
  • It licensed enozertinib from Voronoi for all markets except Greater China, with milestones and royalties owed (10-Q, note 3).

2. Story so far

Last updated Oct 27, 2026. Reflects filings and releases through Oct 23, 2026.

In short: ORIC licensed both of its current drugs in 2020 and has funded their development through private placements, a direct stock sale to Pfizer and at-the-market share offerings; since 2022 its share count, including pre-funded warrants (rights bought upfront that need only $0.0001 a share to exercise), nearly tripled. ORIC announced Phase 3 initiation for its lead drug rinzimetostat on July 14, 2026, and ORIC plans a Phase 3 trial of enozertinib in the first half of 2027. Stock Analysis reports that ORIC fell 32% on Oct 26, 2026, following Johnson & Johnson’s Oct 25 announcement of early data for a rival prostate cancer drug.

Date Milestone Source
Aug 3, 2020 Licenses the PRC2 programme (PRC2 is a protein complex that regulates gene activity) that became rinzimetostat from Mirati for 588,235 ORIC shares; no milestones or royalties 10-Q Q2 2026, note 3
Oct 19, 2020 Licenses enozertinib from Voronoi for $5.0M plus 283,259 shares; up to $111M of development and regulatory milestones 10-Q Q2 2026, note 3
Jul 8, 2021 Sells 2.6M shares at $19.25 ($50.0M) through its at-the-market (ATM) programme 10-K FY2021
Dec 21, 2022 Pfizer buys $25.0M of stock at $4.65 alongside a trial collaboration on ORIC-533; cash runway “into 1H 2025” 8-K
Jun 26, 2023 $85.0M private placement at $7.00; runway “into late 2025” 8-K
Jan 2024 ★ First rinzimetostat Phase 1b data (Jan); $125.0M private placement at $10.00 (Jan 22); runway “into late 2026” 10-Q Q2 2026; 8-K
May 23, 2025 $125.0M private placement at $6.50, partly as pre-funded warrants; runway “into the second half of 2027” 8-K
Aug 12, 2025 Closes its discovery research group, cutting about 20% of staff 8-K
Mar 31, 2026 ★ Picks 400 mg rinzimetostat with darolutamide as the Phase 3 dose; 84% of patients alive without scan-confirmed progression at five months 8-K; Q1 release
Jul 14, 2026 ★ Announces initiation of Himalayas-1, a Phase 3 trial of about 600 patients; Bayer supplies darolutamide free Release
Oct 23, 2026 Enozertinib data at the ESMO congress: investigators assessed confirmed tumour responses in 21 of 25 response-evaluable first-line patients (receiving their first treatment for advanced disease; 84%; 26 patients treated); Phase 3 trial Redwood-1 planned for 1H 2027 8-K
Oct 26, 2026 ★ Stock Analysis reports a 32% fall to $8.96 following J&J’s announcement of early data for its rival drug JNJ-6143. Start of our coverage: ORIC falls 32% after J&J shows early data for a rival prostate cancer drug J&J release; Stock Analysis

3. Latest quarter: did the story change?

Last updated Oct 27, 2026. Reflects Q2 2026 (10-Q filed Aug 3, 2026) and the Oct 23 8-K. Q3 results are expected in mid-November; ORIC has not announced the date.

Bottom line: According to its filings, ORIC started its first Phase 3 trial and kept its cash-runway estimate, but its quarterly loss widened as trial spending rose, its second drug’s Phase 3 start is now planned for 1H 2027, and a rival’s early data has since added a competitive question.

Driver Last quarter → this quarter Management: before → now Signal
Rinzimetostat Phase 3 Phase 3 dose chosen (Mar 31) → Himalayas-1 initiation announced (Jul 14) Guided for 1H 2026 (May 4) → announced Jul 14; initiation date not given (the Bayer supply agreement is dated Jul 7) Unchanged
Enozertinib Phase 1b enrolling → 84% confirmed response rate in 25 first-line patients with atypical EGFR mutations (Oct 23) Potential initiation of registrational trials for both drugs “in 2026” (Nov 13, 2025) → Redwood-1 in 1H 2027 (Oct 23) Watch
Spending Net loss Q1 $35.8M → Q2 $41.5M; R&D $31.4M → $36.3M (rinzimetostat outside costs $12.1M → $16.0M) R&D to “increase substantially” (10-K, Feb 23) → same wording (10-Q, Aug 3) Worse
Cash and runway Cash and investments $419.7M (Mar 31) → $387.6M (Jun 30) “Into 2H 2028” (May 4) → “into 2H 2028” (Aug 3) Unchanged
Competition J&J reported a 75% tumour response rate (12 of 16 measurable patients) for JNJ-6143 (Oct 25); Stock Analysis reports ORIC fell 32% (Oct 26) We found no ORIC statement on the J&J data → none found (Oct 26) Watch

Sources: Q1 2026 release, Q2 2026 release, Q3 2025 release, 10-Q Q1 2026, 10-Q Q2 2026, 8-K, Oct 23, J&J release.

Unresolved questions: when Himalayas-1 reads out (ORIC has said only that its cash should last beyond that readout), how much spending rises with two Phase 3 trials, and whether J&J tests its drug in the earlier-stage patients ORIC is targeting.

4. Buybacks vs real dilution (5 years)

Last updated Oct 27, 2026. Reflects the equity statements in the 10-K FY2023, 10-K FY2025 and 10-Q Q2 2026.

Dilution in one line: common shares plus pre-funded warrants rose 174% from Dec 31, 2021 to Jun 30, 2026, about 25.1% a year compounded. If you owned 1% of ORIC at the end of 2021, you’d own about 0.36% on Jun 30, 2026 without buying more (our calculation)1. None of the new shares were offset by buybacks. Our scale: High (over 3% a year).

Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.

Change in shares outstanding, Dec 31, 2021 to Jun 30, 2026FY2022 +14.4%, FY2023 +27.9%, FY2024 +23.1%, FY2025 +45.1%, H1 2026 +5.0%. Total +174.2% since Dec 31, 2021.0%+50%+100%+150%+200%FY2022: +14.4% in the period; +14.4% since Dec 31, 2021+14.4%FY2022FY2023: +27.9% in the period; +46.3% since Dec 31, 2021+27.9%FY2023FY2024: +23.1% in the period; +80.1% since Dec 31, 2021+23.1%FY2024FY2025: +45.1% in the period; +161.2% since Dec 31, 2021+45.1%FY2025H1 2026 (part year): +5.0% in the period; +174.2% since Dec 31, 2021+5.0%H1 2026+174.2%since Dec 31, 2021

Change in the period Total since Dec 31, 2021 Part year

Shares outstanding at period end (all classes): 39.4M on Dec 31, 2021, 108.1M on Jun 30, 2026, +174.2% (our calculation). A bar below zero means the count fell (net buybacks).

Common shares plus pre-funded warrants (prepaid rights to shares at $0.0001 each), from the author's bridge (10-K and 10-Q equity statements); pre-funded warrants have no standard XBRL tag.

Period endShares outstandingChangeBuybacks (fiscal year)Stock-based pay (fiscal year)Stock pay as % of revenue
H1 2026 (Jun 30, 2026)108.1M+5.0%———
FY2025 (Dec 31, 2025)103.0M+45.1%—$25M—
FY2024 (Dec 31, 2024)71.0M+23.1%—$20M—
FY2023 (Dec 31, 2023)57.7M+27.9%—$15M—
FY2022 (Dec 31, 2022)45.1M+14.4%—$14M—
FY2021 (Dec 31, 2021)39.4M——$13M—

Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.

How we calculated this

Pre-funded warrants are prepaid rights to shares at $0.0001 each; ORIC includes them in its per-share loss count. On common shares alone, the rise is 163%2.

Bridge (millions of shares, incl. pre-funded warrants) 2022 2023 2024 2025 H1 2026 Total
Start of period 39.4 45.1 57.7 71.0 103.0 39.4
Private placements and direct sales (incl. pre-funded warrants) 5.4 12.1 12.5 19.2 – 49.3
At-the-market sales – – – 11.8 4.7 16.5
Stock pay and employee plans (options, restricted stock units, share purchase plan) 0.3 0.5 0.8 1.0 0.4 2.9
Acquisitions or convertible notes 0 0 0 0 0 0
Buybacks 0 0 0 0 0 0
End of period 45.1 57.7 71.0 103.0 108.1 108.1

Totals use unrounded filing figures. Exercising pre-funded warrants (2.86M in 2024, 0.64M in 2025) moved shares from warrants to common stock; ORIC withheld 47 shares in those exercises. 4.46M pre-funded warrants were outstanding at Jun 30, 2026 (10-Q, note 8).

Prices paid and received:

Period Shares bought back Average price paid Spent Shares sold for cash Average price received Raised Sources
2022 — — — 5.38M $4.65 $25.0M 10-K FY2022: Pfizer direct sale
2023 — — — 12.14M $7.00 (our calculation) $85.0M 10-K FY2023: 9.29M shares at $7.00 and 2.86M pre-funded warrants at $6.9999
2024 — — — 12.50M $10.00 $125.0M 10-K FY2024: private placement
2025 — — — 31.01M $7.88 (our calculation) $244.4M 10-K FY2025: 19.23M shares and pre-funded warrants at $6.50 ($125.0M); 11.78M ATM shares at a $10.13 average ($119.4M, our calculation)3
2026 to date (Jan 1–Jun 30) — — — 4.70M $12.96 $60.9M 10-Q Q2 2026, note 1 and cash flow statement

ORIC has sold shares for cash every year since 2022 (private placements, a Pfizer direct sale and at-the-market sales) and has never bought any back. Averages are derived (our calculation)4.

Basis and details
  • Prices are per share; ORIC has not split its stock since listing in April 2020. Raised is gross proceeds before costs.
  • Employee option exercises and share-purchase-plan sales are excluded. ORIC has never bought back stock.
  • No sale after Jun 30 had been disclosed by Oct 27; the share count was 103.65M on Jul 27 (10-Q, cover).
  • For reference, Stock Analysis reports a $9.00 closing price on Oct 27, 2026 (Stock Analysis).
Stock-based pay 2022 2023 2024 2025 H1 2026
$M 14.5 15.2 20.2 25.0 14.0
% of operating expenses (our calculation; ORIC has no revenue) 16% 14% 14% 18% 16%

Employee awards already granted are a further source of new shares. In June 2026 shareholders approved lowering the plan’s annual top-up rate from 5% to 4% while removing its 2.66M-share annual cap, so the annual addition can be larger.

Employee awards and the share plan
  • At Jun 30, 2026, 17.15M options (average exercise price $6.92) and 1.12M restricted stock units (awards that deliver shares when vesting conditions are met) were outstanding.
  • Since June 2026, the plan’s yearly automatic top-up is 4% of outstanding shares (was 5%), without the former 2.66M-share limit (8-K, Jun 22).

5. Profit vs cash (latest FY and TTM)

Last updated Oct 27, 2026. Reflects the 10-K FY2025, the 10-Q Q2 2025 and the 10-Q Q2 2026. ORIC reports no adjusted profit measure.

ORIC’s cash outflow is close to its net loss; stock-based pay is the main non-cash cost.

$M FY2025 Trailing twelve months (TTM) to Jun 30, 2026 (our calculation)5
Net loss −129.5 −140.4
Adjusted metric Not reported Not reported
Operating cash flow −111.0 −111.6
Capital spending −0.7 −0.6
Free cash flow (our calculation)6 −111.7 −112.3

The items between the loss and the cash flow are small. Grouped by what each means for future profit and cash:

Helps future profit or cash:

  • None identified.

Hurts future profit or cash:

  • Stock-based pay added back $25.0M in 2025 ($25.9M TTM): Not a cash cost, but it is a cost in the loss and it adds shares (see section 4).

One-off / no lasting effect:

  • Lower payables and accrued costs used $7.2M of cash in 2025; prepaid and other assets released $1.8M (10-K, cash flow statement): A timing difference between profit and cash.
  • Interest income accrued on discounted Treasury bills ($2.3M in 2025): A timing difference: counted in the loss before the cash arrives at maturity.
The raw reconciling items
  • Stock-based pay added back $25.0M in 2025 ($25.9M TTM).
  • Lower payables and accrued costs used $7.2M of cash in 2025; prepaid and other assets released $1.8M (10-K, cash flow statement).
  • Interest income accrued on discounted Treasury bills ($2.3M in 2025) is counted in the loss before the cash arrives at maturity.

Funding: how long without new money? (our calculation; as of Jun 30, 2026, the latest filed balance sheet)

  • Cash, cash equivalents and investments of $387.6M (all US Treasuries and money-market funds) cover about 3.5 years, or 14 quarters, of TTM free cash outflow of $112.3M (our calculation)7, but ORIC itself says cash should fund its plan “into the second half of 2028” (10-Q).
Funding details
  • ORIC expects R&D to “increase substantially” as trials advance, which is why its estimate is shorter than our past-rate path.
  • ORIC has no debt or convertible notes, and its 10-Q discloses no credit lines.
  • ATM programme: $200.0M, opened Feb 26, 2026 with Jefferies (8-K). About $159M remained at Jun 30 (our calculation)8.
  • Exercising the 4.46M pre-funded warrants would bring in almost no cash ($0.0001 each).
  • This is based on past cash flow; spending plans can change it.

Extends the runway:

  • None committed. There is no credit line, and no share sale after Jun 30 had been disclosed by Oct 27.

Shortens the runway:

  • None (no debt, maturities or covenants).

Conditional:

  • The at-the-market programme (about $159M left), which brings in cash only if ORIC sells shares; and Voronoi milestones of up to $111M, which ORIC would owe only if development milestones are met, with no dates disclosed.

Cash path (our calculation; an illustration, not a forecast):

At the past rate and with known items, cash would fall below zero in Q4 2029; the company itself says its cash will last into the second half of 2028 (10-Q), because it expects research and development spending to “increase substantially”.

Illustration, not a forecast.

Cash path: ending cash by quarter (illustration)Start $388M, Q3 2026 $360M, Q4 2026 $331M, Q1 2027 $303M, Q2 2027 $275M, Q3 2027 $247M, Q4 2027 $219M, Q1 2028 $191M, Q2 2028 $163M, Q3 2028 $135M, Q4 2028 $107M, Q1 2029 $79M, Q2 2029 $51M, Q3 2029 $23M, Q4 2029 −$5M.Q4 2028: raising window (under a year of usual spending left)Q1 2029: raising window (under a year of usual spending left)Q2 2029: raising window (under a year of usual spending left)Q3 2029: raising window (under a year of usual spending left)Q4 2029: would need new money−$100M$0M$100M$200M$300M$400MStart: $388MQ3 2026: $360MQ4 2026: $331MQ1 2027: $303MQ2 2027: $275MQ3 2027: $247MQ4 2027: $219MQ1 2028: $191MQ2 2028: $163MQ3 2028: $135MQ4 2028: $107MQ1 2029: $79MQ2 2029: $51MQ3 2029: $23MQ4 2029: −$5MStartQ4 2026Q2 2027Q4 2027Q2 2028Q4 2028Q2 2029Q4 2029

Ending cash (cash, equivalents and marketable securities) Known item Raising window (under a year of usual spending left) Would need new money

Quarter Starting cash Usual spending Known items Ending cash Sources / notes
Q3 2026 +387.6 −28.1 0.0 +359.5 No share sale after Jun 30 disclosed by Oct 27
Q4 2026 +359.5 −28.1 0.0 +331.4
Q1 2027 +331.4 −28.1 0.0 +303.4
Q2 2027 +303.4 −28.1 0.0 +275.3
Q3 2027 +275.3 −28.1 0.0 +247.2
Q4 2027 +247.2 −28.1 0.0 +219.2
Q1 2028 +219.2 −28.1 0.0 +191.1
Q2 2028 +191.1 −28.1 0.0 +163.0
Q3 2028 +163.0 −28.1 0.0 +135.0 ORIC’s own runway estimate ends “into 2H 2028”
Q4 2028 +135.0 −28.1 0.0 +106.9 Less than a year of usual spending left.
Q1 2029 +106.9 −28.1 0.0 +78.9 Less than a year of usual spending left.
Q2 2029 +78.9 −28.1 0.0 +50.8 Less than a year of usual spending left.
Q3 2029 +50.8 −28.1 0.0 +22.7 Less than a year of usual spending left.
Q4 2029 +22.7 −28.1 0.0 −5.3

Amounts in $M.

At the past rate and with known items, cash would fall below zero in Q4 2029; the company itself says its cash will last into the second half of 2028 (10-Q), because it expects research and development spending to “increase substantially”. Our path assumes flat spending at the past rate. Companies usually raise money well before that; quarters with less than a year of usual spending left are shaded.

What the cash path counts:

  • Usual spending: about −$28.1M a quarter, held flat.
  • Known items: none dated. ORIC has no debt, no acquisitions and no minimum purchase commitments.
How we calculated this

Usual spending is TTM free cash flow (−$112.3M, Q3 2025–Q2 2026) ÷ 4 ≈ −$28.1M a quarter, held flat. Calculations use unrounded amounts (starting cash $387.560M, quarterly spending −$28.0645M); displayed values are rounded to $0.1M. Starting cash is cash, cash equivalents and investments at Jun 30, 2026. ORIC has disclosed no dated known items: no debt, no acquisitions and no minimum purchase commitments (10-K, MD&A). Lease payments and ordinary trial and manufacturing costs are already in past free cash flow, so they are not added. Capital spending is small ($0.6M TTM, $0.7M in 2025, $1.2M in 2024) and ORIC has disclosed no capital-spending plan. Not included: Voronoi milestones of up to $111M, with no dates disclosed.

6. Customer and contract exposure

Last updated Oct 27, 2026. Reflects the 10-K FY2025, the 10-Q Q2 2026 and releases through Oct 23, 2026.

ORIC has no customers or revenue. Its exposure lies in two licences (rinzimetostat is royalty-free from Mirati; enozertinib carries milestones and royalties to Voronoi) and in drug supply from Bayer and J&J, which also develops a rival prostate cancer drug.

Licence and supply contracts
Contract Signed Terms Source
Mirati (Bristol Myers Squibb) licence: rinzimetostat Aug 3, 2020 Worldwide, royalty-free; paid in shares. Mirati may end it if ORIC challenges the patents or stops development; ORIC may end it on notice 10-Q, note 3
Voronoi licence: enozertinib Oct 19, 2020 All markets except Greater China. Up to $111M of development and regulatory milestones and $225M of sales milestones, plus royalties. ORIC paid $5.0M upfront plus 283,259 shares, and a further $5.0M development milestone in Q3 2022 10-Q, note 3
Bayer supply: darolutamide May 14, 2024; Jul 7, 2026 (Phase 3) Free supply; Bayer gets no rights to rinzimetostat 10-Q, note 3
J&J supply: apalutamide and amivantamab Jul 10 and Aug 29, 2024 Supply for combination trials; ORIC keeps all rights 10-Q, note 3
Cancer Research UK: ORIC-259 (early-stage) Oct 5, 2026 The charity funds and runs development through Phase 1/2; ORIC can take the rights back afterwards, with milestones and royalties owed to the charity Release
  • J&J supplies ORIC’s trials and also develops JNJ-6143, a rival prostate cancer drug (J&J release).
  • ORIC’s issued US patents on rinzimetostat as a compound are expected to expire in 2039, before any extension (10-K, Item 1).

7. What to watch

Last updated Oct 27, 2026. Reflects the 10-Q for Q2 2026, the Q2 2026 release, the Oct 23 8-K and the Q3 2025 release (last year’s results date).

Date Item Source
Mid-Nov 2026 (not yet announced) Q3 2026 results. Last year’s Q3 results came out on Nov 13, 2025; MarketBeat estimates Nov 12, 2026 (reported, not confirmed by ORIC) Q3 2025 release; MarketBeat
2H 2026 Rinzimetostat programme update; enozertinib data in first-line exon 20 patients, alone and with amivantamab Q2 2026 release
1H 2027 Planned start of Redwood-1, the Phase 3 trial of enozertinib (about 360 patients) 8-K, Oct 23
2H 2028 End of ORIC’s own cash-runway estimate. ORIC says this is after the expected main readout of Himalayas-1, but has not given a readout date Q2 2026 release

Valuation at each update

At the close used for each update, from the filings available then. Frozen when the update is published; never revised.

UpdateCloseMarket valueEVP/SEV/salesP/EP/FCFRevenue growthFCF marginNet cash (debt)Basis
Oct 27, 2026$8.96 (Oct 26)$929M$541Mn/mn/mn/mn/mn/mn/m$388M12 months to Jun 30, 2026; pre-revenue

Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Jun 30, 2026, filed Aug 3, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 27, 2026 row: Corrected Oct 31, 2026: market value now uses common shares outstanding (103.7 million on the 10-Q cover page, Jul 27, 2026), our standard basis, instead of 108.1 million shares including pre-funded warrants; market value $929M (was $969M) and enterprise value recalculated. Price and date unchanged.

Notes and calculations

  1. Our calculations: growth = (108.100 ÷ 39.430 − 1) × 100 ≈ 174%; annual rate = [(108.100 ÷ 39.430)^(1 ÷ 4.5) − 1] × 100 ≈ 25.1%; remaining ownership = 1% × 39.430 ÷ 108.100 ≈ 0.36% (39.4M ÷ 108.1M). ↩

  2. 103.6M ÷ 39.4M − 1. ↩

  3. $244.4M cash-flow total − $125.0M. ↩

  4. Gross proceeds ÷ shares and pre-funded warrants sold. ↩

  5. FY2025 − H1 2025 + H1 2026. ↩

  6. Operating cash flow + capital spending. ↩

  7. $387.6M ÷ $112.3M. ↩

  8. $200.0M − ($60.9M H1 gross − about $20.3M sold under the earlier prospectus through Feb 23, 2026). The $20.3M is our calculation: $139.7M cumulative gross proceeds under the earlier prospectus − $119.4M FY2025 gross proceeds. ↩

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

About ORIC Pharmaceuticals: Website (external site)Investor relations (external site)SEC filings (external site)